<!DOCTYPE pdf2xml SYSTEM "pdf2xml.dtd">
<pdf2xml producer="poppler" version="23.04.0">
<page number="1" position="absolute" top="0" left="0" height="792" width="612">
	<fontspec id="font0" size="9" family="Arial,Italic" color="#000000"/>
	<fontspec id="font1" size="9" family="Arial" color="#000000"/>
	<fontspec id="font2" size="9" family="Arial,Bold" color="#000000"/>
	<fontspec id="font3" size="7" family="Arial,Italic" color="#000000"/>
	<fontspec id="font4" size="10" family="Giovanni-Book" color="#000000"/>
	<fontspec id="font5" size="9" family="GillSans,BoldItalic" color="#000000"/>
	<fontspec id="font6" size="11" family="GillSans,Bold" color="#000000"/>
	<fontspec id="font7" size="8" family="GillSans,Bold" color="#000000"/>
	<fontspec id="font8" size="8" family="GillSans" color="#000000"/>
<text top="41" left="55" width="113" height="10" font="font0" id="p1_t1" reading_order_no="0" segment_no="0" tag_type="title">BMC Dermatology 2006, 6 :8<i>BMC Dermatology</i></text>
<text top="41" left="373" width="181" height="10" font="font1" id="p1_t2" reading_order_no="1" segment_no="1" tag_type="text">http://www.biomedcentral.com/1471-5945/6/8</text>
<text top="756" left="508" width="46" height="10" font="font1" id="p1_t3" reading_order_no="98" segment_no="17" tag_type="text">Page 4 of 6<b>6</b></text>
<text top="769" left="432" width="122" height="8" font="font3" id="p1_t4" reading_order_no="99" segment_no="18" tag_type="text">(page number not for citation purposes)</text>
<text top="87" left="55" width="241" height="9" font="font4" id="p1_t5" reading_order_no="2" segment_no="2" tag_type="text">12 was based on the cohort of patients for whom DLQI</text>
<text top="98" left="55" width="241" height="9" font="font4" id="p1_t6" reading_order_no="3" segment_no="2" tag_type="text">was available. In these patients 34.3% of patients</text>
<text top="110" left="55" width="241" height="9" font="font4" id="p1_t7" reading_order_no="4" segment_no="2" tag_type="text">achieved SPC on efalizumab, compared with 7.3% on pla-<i>(page number not for citation purposes)</i></text>
<text top="122" left="55" width="64" height="9" font="font4" id="p1_t8" reading_order_no="5" segment_no="2" tag_type="text">cebo (Table 3).</text>
<text top="145" left="55" width="241" height="9" font="font4" id="p1_t9" reading_order_no="6" segment_no="4" tag_type="text">In high-need patients, only 4/117 patients (3.4%) given</text>
<text top="157" left="55" width="241" height="9" font="font4" id="p1_t10" reading_order_no="7" segment_no="4" tag_type="text">placebo achieved SPC at week 12, compared with 73/221</text>
<text top="169" left="55" width="146" height="9" font="font4" id="p1_t11" reading_order_no="8" segment_no="4" tag_type="text">(33.0%) on efalizumab (Figure 1).<a href="">bo (Table 3).</a></text>
<text top="192" left="55" width="241" height="9" font="font4" id="p1_t12" reading_order_no="9" segment_no="6" tag_type="text">Observed response rates at week 12 were lower in the pro-</text>
<text top="204" left="55" width="241" height="9" font="font4" id="p1_t13" reading_order_no="10" segment_no="6" tag_type="text">spective validation compared with the retrospective rates.</text>
<text top="216" left="55" width="241" height="9" font="font4" id="p1_t14" reading_order_no="11" segment_no="6" tag_type="text">However, the rate differences between active and placebo<a href="">1).</a></text>
<text top="228" left="55" width="241" height="9" font="font4" id="p1_t15" reading_order_no="12" segment_no="6" tag_type="text">observed in the prospective study (27% for the total study</text>
<text top="239" left="55" width="241" height="9" font="font4" id="p1_t16" reading_order_no="13" segment_no="6" tag_type="text">group and 30% for the high need group) were similar to</text>
<text top="251" left="55" width="190" height="9" font="font4" id="p1_t17" reading_order_no="14" segment_no="6" tag_type="text">that seen in the retrospective analyses (29%).</text>
<text top="275" left="55" width="135" height="9" font="font5" id="p1_t18" reading_order_no="15" segment_no="8" tag_type="title">Comparison of PASI-75 and SPC</text>
<text top="286" left="55" width="241" height="9" font="font4" id="p1_t19" reading_order_no="16" segment_no="9" tag_type="text">The efficacy-only measure, PASI 75, was compared with</text>
<text top="298" left="55" width="241" height="9" font="font4" id="p1_t20" reading_order_no="17" segment_no="9" tag_type="text">the multidimensional SPC for pooled retrospective data</text>
<text top="310" left="55" width="241" height="9" font="font4" id="p1_t21" reading_order_no="18" segment_no="9" tag_type="text">from the three studies (ACD 2058, 2059, and 2390). This<i><b>Comparison of PASI-75 and SPC</b></i></text>
<text top="322" left="55" width="241" height="9" font="font4" id="p1_t22" reading_order_no="19" segment_no="9" tag_type="text">showed that 27.3% of patients treated with efalizumab</text>
<text top="333" left="55" width="241" height="9" font="font4" id="p1_t23" reading_order_no="20" segment_no="9" tag_type="text">achieved PASI 75 at week 12, while 39.4% of patients</text>
<text top="345" left="55" width="103" height="9" font="font4" id="p1_t24" reading_order_no="21" segment_no="9" tag_type="text">achieved SPC (Figure 2).</text>
<text top="369" left="55" width="129" height="10" font="font6" id="p1_t25" reading_order_no="22" segment_no="10" tag_type="title">Discussion and conclusion</text>
<text top="380" left="55" width="241" height="9" font="font4" id="p1_t26" reading_order_no="23" segment_no="11" tag_type="text">Efalizumab has been studied in more than 3500 patients.</text>
<text top="392" left="55" width="241" height="9" font="font4" id="p1_t27" reading_order_no="24" segment_no="11" tag_type="text">This extensive database offers an ideal source of informa-<a href="">C (Figure 2).</a></text>
<text top="404" left="55" width="241" height="9" font="font4" id="p1_t28" reading_order_no="25" segment_no="11" tag_type="text">tion for assessing traditional measures of efficacy, and<b>Discussion and conclusion</b></text>
<text top="416" left="55" width="241" height="9" font="font4" id="p1_t29" reading_order_no="26" segment_no="11" tag_type="text">generating new measures of benefit to assess whether a</text>
<text top="427" left="55" width="241" height="9" font="font4" id="p1_t30" reading_order_no="27" segment_no="11" tag_type="text">patient's psoriasis is controlled. The SPC assessment</text>
<text top="439" left="55" width="241" height="9" font="font4" id="p1_t31" reading_order_no="28" segment_no="11" tag_type="text">moves away from an approach focused primarily on treat-</text>
<text top="451" left="55" width="241" height="9" font="font4" id="p1_t32" reading_order_no="29" segment_no="11" tag_type="text">ment difference in PASI 75 response in isolation, to an</text>
<text top="463" left="55" width="241" height="9" font="font4" id="p1_t33" reading_order_no="30" segment_no="11" tag_type="text">approach that would further characterize each patient's</text>
<text top="474" left="55" width="241" height="9" font="font4" id="p1_t34" reading_order_no="31" segment_no="11" tag_type="text">response to treatment, leading to a better understanding</text>
<text top="486" left="55" width="241" height="9" font="font4" id="p1_t35" reading_order_no="32" segment_no="11" tag_type="text">of the benefit:risk that should be expected in psoriasis</text>
<text top="498" left="55" width="43" height="9" font="font4" id="p1_t36" reading_order_no="33" segment_no="11" tag_type="text">treatment.</text>
<text top="521" left="55" width="241" height="9" font="font4" id="p1_t37" reading_order_no="34" segment_no="13" tag_type="text">Using conventional, uni-dimensional assessment meas-</text>
<text top="533" left="55" width="241" height="9" font="font4" id="p1_t38" reading_order_no="35" segment_no="13" tag_type="text">ures such as PASI 75 and DLQI, efalizumab has already</text>
<text top="545" left="55" width="241" height="9" font="font4" id="p1_t39" reading_order_no="36" segment_no="13" tag_type="text">been demonstrated to be significantly more effective than</text>
<text top="557" left="55" width="241" height="9" font="font4" id="p1_t40" reading_order_no="37" segment_no="13" tag_type="text">placebo. However, the use of these physician- or patient-</text>
<text top="568" left="55" width="241" height="9" font="font4" id="p1_t41" reading_order_no="38" segment_no="13" tag_type="text">assessed scales either alone, or independently of each</text>
<text top="580" left="55" width="241" height="9" font="font4" id="p1_t42" reading_order_no="39" segment_no="13" tag_type="text">other, does not accurately demonstrate the multidimen-</text>
<text top="592" left="55" width="241" height="9" font="font4" id="p1_t43" reading_order_no="40" segment_no="13" tag_type="text">sional effect that efalizumab has in safely controlling pso-</text>
<text top="604" left="55" width="241" height="9" font="font4" id="p1_t44" reading_order_no="41" segment_no="13" tag_type="text">riasis. Studies indicate that there is a need to consider</text>
<text top="87" left="313" width="241" height="9" font="font4" id="p1_t45" reading_order_no="42" segment_no="3" tag_type="text">psoriasis and its treatment not just in terms of objective</text>
<text top="98" left="313" width="241" height="9" font="font4" id="p1_t46" reading_order_no="43" segment_no="3" tag_type="text">assessments of lesion severity, but also in terms of the</text>
<text top="110" left="313" width="241" height="9" font="font4" id="p1_t47" reading_order_no="44" segment_no="3" tag_type="text">impact of the disease on patients' lives [16,17]. The inclu-</text>
<text top="122" left="313" width="241" height="9" font="font4" id="p1_t48" reading_order_no="45" segment_no="3" tag_type="text">sion of the safety component in the SPC endpoint allows</text>
<text top="134" left="313" width="241" height="9" font="font4" id="p1_t49" reading_order_no="46" segment_no="3" tag_type="text">a simple benefit:risk assessment to be made, as the end-</text>
<text top="145" left="313" width="241" height="9" font="font4" id="p1_t50" reading_order_no="47" segment_no="3" tag_type="text">point describes the proportion of patients who had bene-<a href="">ves [16</a>,<a href="">17]. T</a>he inclu-</text>
<text top="157" left="313" width="123" height="9" font="font4" id="p1_t51" reading_order_no="48" segment_no="3" tag_type="text">fit without major side effects.</text>
<text top="181" left="313" width="241" height="9" font="font4" id="p1_t52" reading_order_no="49" segment_no="5" tag_type="text">We applied this new outcome measure – SPC – using</text>
<text top="192" left="313" width="241" height="9" font="font4" id="p1_t53" reading_order_no="50" segment_no="5" tag_type="text">week 12 data obtained from studies that had already been</text>
<text top="204" left="313" width="241" height="9" font="font4" id="p1_t54" reading_order_no="51" segment_no="5" tag_type="text">completed and analyzed using conventional uni-dimen-</text>
<text top="216" left="313" width="241" height="9" font="font4" id="p1_t55" reading_order_no="52" segment_no="5" tag_type="text">sional measures such as PASI, and evaluated SPC prospec-</text>
<text top="228" left="313" width="241" height="9" font="font4" id="p1_t56" reading_order_no="53" segment_no="5" tag_type="text">tively in a new study (IMP 24011) that had not been</text>
<text top="239" left="313" width="175" height="9" font="font4" id="p1_t57" reading_order_no="54" segment_no="5" tag_type="text">completed at the time SPC was described.</text>
<text top="263" left="313" width="241" height="9" font="font4" id="p1_t58" reading_order_no="55" segment_no="7" tag_type="text">A favorable overall benefit:risk profile as determined by</text>
<text top="275" left="313" width="241" height="9" font="font4" id="p1_t59" reading_order_no="56" segment_no="7" tag_type="text">the SPC endpoint was confirmed in nearly 40% of all the</text>
<text top="286" left="313" width="241" height="9" font="font4" id="p1_t60" reading_order_no="57" segment_no="7" tag_type="text">patients treated with efalizumab for 12 weeks. Using SPC</text>
<text top="298" left="313" width="241" height="9" font="font4" id="p1_t61" reading_order_no="58" segment_no="7" tag_type="text">in both prospective and retrospective clinical trial analy-</text>
<text top="310" left="313" width="241" height="9" font="font4" id="p1_t62" reading_order_no="59" segment_no="7" tag_type="text">ses, efalizumab consistently demonstrated superiority</text>
<text top="322" left="313" width="241" height="9" font="font4" id="p1_t63" reading_order_no="60" segment_no="7" tag_type="text">over placebo, demonstrating that many patients achieve</text>
<text top="333" left="313" width="241" height="9" font="font4" id="p1_t64" reading_order_no="61" segment_no="7" tag_type="text">disease control without major safety issues, and at the</text>
<text top="345" left="313" width="241" height="9" font="font4" id="p1_t65" reading_order_no="62" segment_no="7" tag_type="text">same time experience an improved quality of life. Impor-</text>
<text top="357" left="313" width="241" height="9" font="font4" id="p1_t66" reading_order_no="63" segment_no="7" tag_type="text">tantly, efalizumab was similarly effective in high-need</text>
<text top="369" left="313" width="241" height="9" font="font4" id="p1_t67" reading_order_no="64" segment_no="7" tag_type="text">patients. Also, even amongst those patients who did not</text>
<text top="380" left="313" width="241" height="9" font="font4" id="p1_t68" reading_order_no="65" segment_no="7" tag_type="text">manage to achieve SPC, approximately 9% achieved PASI</text>
<text top="392" left="313" width="241" height="9" font="font4" id="p1_t69" reading_order_no="66" segment_no="7" tag_type="text">75 after 12 weeks of treatment with efalizumab 1.0 mg/kg,</text>
<text top="404" left="313" width="218" height="9" font="font4" id="p1_t70" reading_order_no="67" segment_no="7" tag_type="text">compared with less than 1% of patients on placebo.</text>
<text top="427" left="313" width="241" height="9" font="font4" id="p1_t71" reading_order_no="68" segment_no="12" tag_type="text">Improvement in the management of psoriasis is particu-</text>
<text top="439" left="313" width="241" height="9" font="font4" id="p1_t72" reading_order_no="69" segment_no="12" tag_type="text">larly welcome as the impact of the disease, particularly</text>
<text top="451" left="313" width="241" height="9" font="font4" id="p1_t73" reading_order_no="70" segment_no="12" tag_type="text">among high-need patients, and shortcomings of current</text>
<text top="463" left="313" width="241" height="9" font="font4" id="p1_t74" reading_order_no="71" segment_no="12" tag_type="text">treatments are becoming more widely recognized. Current</text>
<text top="474" left="313" width="241" height="9" font="font4" id="p1_t75" reading_order_no="72" segment_no="12" tag_type="text">management of patients with moderate-to-severe plaque</text>
<text top="486" left="313" width="241" height="9" font="font4" id="p1_t76" reading_order_no="73" segment_no="12" tag_type="text">psoriasis involves systemic therapies, such as cyclosporin,</text>
<text top="498" left="313" width="241" height="9" font="font4" id="p1_t77" reading_order_no="74" segment_no="12" tag_type="text">methotrexate, acitretin and PUVA, which are associated</text>
<text top="510" left="313" width="241" height="9" font="font4" id="p1_t78" reading_order_no="75" segment_no="12" tag_type="text">with treatment-limiting systemic cumulative toxicities.</text>
<text top="521" left="313" width="241" height="9" font="font4" id="p1_t79" reading_order_no="76" segment_no="12" tag_type="text">The use of biological agents such as efalizumab that mod-</text>
<text top="533" left="313" width="241" height="9" font="font4" id="p1_t80" reading_order_no="77" segment_no="12" tag_type="text">ulate the activation of T-cells and their migration into the</text>
<text top="545" left="313" width="241" height="9" font="font4" id="p1_t81" reading_order_no="78" segment_no="12" tag_type="text">dermal and epidermal tissues may provide more targeted</text>
<text top="557" left="313" width="241" height="9" font="font4" id="p1_t82" reading_order_no="79" segment_no="12" tag_type="text">therapy with an improved safety profile. Our findings,</text>
<text top="568" left="313" width="241" height="9" font="font4" id="p1_t83" reading_order_no="80" segment_no="12" tag_type="text">and those of prior trials of efalizumab, support this con-</text>
<text top="580" left="313" width="241" height="9" font="font4" id="p1_t84" reading_order_no="81" segment_no="12" tag_type="text">cept and demonstrate promising opportunities to</text>
<text top="592" left="313" width="241" height="9" font="font4" id="p1_t85" reading_order_no="82" segment_no="12" tag_type="text">improve therapy. The observations of substantial disease</text>
<text top="633" left="55" width="164" height="7" font="font7" id="p1_t86" reading_order_no="83" segment_no="14" tag_type="title">Table 3: Prospective SPC results at week 12</text>
<text top="651" left="84" width="70" height="7" font="font8" id="p1_t87" reading_order_no="84" segment_no="15" tag_type="table">Study IMP 24011[15]</text>
<text top="651" left="252" width="60" height="7" font="font8" id="p1_t88" reading_order_no="85" segment_no="15" tag_type="table">Treatment Group</text>
<text top="651" left="419" width="98" height="7" font="font8" id="p1_t89" reading_order_no="86" segment_no="15" tag_type="table">Safe Psoriasis Control (SPC)*<b>Table 3: Prospective SPC results at week 12</b></text>
<text top="673" left="89" width="60" height="7" font="font8" id="p1_t90" reading_order_no="87" segment_no="15" tag_type="table">Total study group</text>
<text top="673" left="187" width="59" height="7" font="font8" id="p1_t91" reading_order_no="88" segment_no="15" tag_type="table">Placebo (n = 165)</text>
<text top="673" left="451" width="34" height="7" font="font8" id="p1_t92" reading_order_no="89" segment_no="15" tag_type="table">12 (7.3 %)</text>
<text top="683" left="187" width="115" height="7" font="font8" id="p1_t93" reading_order_no="90" segment_no="15" tag_type="table">Efalizumab 1.0 mg/kg/wk (n = 329)</text>
<text top="683" left="447" width="42" height="7" font="font8" id="p1_t94" reading_order_no="91" segment_no="15" tag_type="table">113 (34.3 %)</text>
<text top="694" left="91" width="56" height="7" font="font8" id="p1_t95" reading_order_no="92" segment_no="15" tag_type="table">High need group</text>
<text top="694" left="187" width="59" height="7" font="font8" id="p1_t96" reading_order_no="93" segment_no="15" tag_type="table">Placebo (n = 117)</text>
<text top="694" left="453" width="30" height="7" font="font8" id="p1_t97" reading_order_no="94" segment_no="15" tag_type="table">4 (3.4 %)</text>
<text top="704" left="187" width="115" height="7" font="font8" id="p1_t98" reading_order_no="95" segment_no="15" tag_type="table">Efalizumab 1.0 mg/kg/wk (n = 221)</text>
<text top="704" left="449" width="38" height="7" font="font8" id="p1_t99" reading_order_no="96" segment_no="15" tag_type="table">73 (33.0 %)</text>
<text top="726" left="59" width="408" height="7" font="font8" id="p1_t100" reading_order_no="97" segment_no="16" tag_type="text">* SPC is defined by PASI &lt;= 8 and DLQI &lt;= 6 and No SAEs and No Severe AEs related to Study Drug and not withdrawn</text>
</page>
</pdf2xml>
